NOX — Noxopharm Income Statement
0.000.00%
Last trade - 00:00
- AU$20.46m
- AU$15.30m
- AU$6.07m
- 66
- 18
- 62
- 49
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.94 | 8.34 | 5.75 | 5.45 | 6.07 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.5 | 16.4 | 20.2 | 15.2 | 16.7 |
Operating Profit | -12.6 | -8.02 | -14.5 | -9.76 | -10.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.6 | -1 | -9.35 | -18.7 | -15.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.6 | -1 | -9.35 | -18.7 | -15.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -11.2 | -0.272 | -9.35 | -18.7 | -15.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.2 | -0.272 | -9.35 | -18.7 | -15.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.08 | -0.002 | -0.035 | -0.064 | -0.052 |